H101 Plus TACE for r/m HNSCC
A phase 2 trial of H101 oncolytic adenovirus in Head and neck squamous cell carcinoma, run by West China Hospital, now recruiting.
Overview
H101 Plus TACE for r/m HNSCC is a phase 2 interventional study registered as NCT07398664 by West China Hospital, with 20 participants planned, started 2026-03-02 and due to reach its primary completion in 2028-06-15. Interventions recorded: H101, TACE. Conditions recorded: Head and Neck Squamous Cell Carcinoma, Oncolytic Virus, TACE.
Linked to the drug H101 oncolytic adenovirus because the registry names it among its interventions and Head and neck squamous cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialHAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B
Shares H101 oncolytic adenovirus and the tag pipeline.
- TrialMIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialSystemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients
Shares H101 oncolytic adenovirus and the tag pipeline.
- TrialA Study of DM005 in Patients With Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialA Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC.
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialIntratumoral N17350 in Advanced Solid Tumors
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialResponse Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC
Shares Head and neck squamous cell carcinoma and the tag pipeline.
- TrialFID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma
Shares Head and neck squamous cell carcinoma and the tag pipeline.